GET DAILY SIGNALSQuidelOrtho (QDEL) Drops -36% in 30 Days: Dissecting the Diagnostics Pressure
Key Takeaways
- QDEL has declined -36% over the past 30 days, driven primarily by a weaker-than-expected flu season impacting respiratory diagnostics demand and disappointing 2026 guidance.
- Over the past quarter, the stock has fallen -63%, reflecting broader challenges in the diagnostics sector amid moderating infectious disease activity.
- Key factors include performance in core segments like Labs and Point-of-Care diagnostics, alongside healthcare sector trends and institutional investor sentiment.
- Post-Q4 2025 earnings, despite an earnings per share (EPS) beat, shares dropped sharply due to conservative full-year outlook.
- Macro trends such as reduced seasonal illnesses have pressured revenue expectations for QuidelOrtho's immunoassay and molecular testing products.
Understanding QuidelOrtho (QDEL) and Its Business Focus
QuidelOrtho Corporation (QDEL) centers on in vitro diagnostics, delivering testing solutions across key business segments rather than tracking a traditional index. These include Labs (clinical chemistry and immunoassay tests), Transfusion Medicine (blood typing and donor screening), Point of Care (rapid testing instruments), and Molecular Diagnostics (PCR-based syndromic testing). The company's exposure is concentrated in healthcare, specifically medical devices and diagnostics, with operations in North America, Europe, and emerging markets.
From what I see, this structure explains much of the recent price behavior: heavy reliance on seasonal respiratory illnesses for revenue makes QDEL vulnerable to milder flu seasons, while transfusion and point-of-care segments offer some diversification. Sector allocation is nearly 100% healthcare, amplifying sensitivity to diagnostic demand cycles and reimbursement trends.
QDEL Price Performance: 30 Days Compared to the Quarter
Over the last 30 days, QDEL's price fell from approximately $19.12 to $12.15, a decline of -36%. The movement was volatile and trend-driven downward, with sharp drops following earnings commentary and flu season updates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In the past quarter, the stock dropped from around $33.20 to $12.15, marking a -63% decrease. Performance was range-bound early but accelerated lower amid negative catalysts, underperforming broader healthcare benchmarks.
Key Drivers of QDEL's 30-Day Decline
The -36% drop in QDEL over the past 30 days stemmed mainly from a moderate flu season reducing demand for respiratory diagnostics, a core revenue driver. QuidelOrtho's Labs and Point-of-Care segments, which include rapid antigen tests and immunoassays, saw pressured sales expectations as infectious disease activity waned.
Q4 2025 earnings on February 11, 2026, reported an EPS beat of $0.46 versus $0.43 expected, but 2026 guidance disappointed investors with conservative revenue projections tied to seasonal weakness. Healthcare sector performance was mixed, but diagnostics lagged amid lower illness incidence. Institutional flows showed reduced positioning by major holders like BlackRock and Vanguard, contributing to selling pressure. Market sentiment shifted negative on diagnostics cyclicality, directly impacting QDEL's valuation.
Breaking Down QDEL's Quarterly Performance
QDEL's -63% quarterly decline reflected sustained weakness in diagnostics demand, exacerbated by a milder respiratory season across Labs and Molecular segments. Broader macroeconomic conditions, including stable interest rates but softening healthcare spending growth, added headwinds.
Top exposures in transfusion medicine provided limited offset, as blood screening volumes remained steady but insufficient to counter respiratory shortfalls. Institutional outflows from healthcare-focused vehicles holding QDEL amplified the downturn. Cumulative impacts from prior guidance revisions and sector cycles in medical devices led to derating, with QDEL underperforming peers like the XLV healthcare ETF.
Tickeron’s AI Screener: A Tool I Rely On
In my own research and trading, I frequently use Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool that helps filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows scanning thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. This identifies trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. I find it particularly useful for enhancing analysis on stocks like QDEL and uncovering hidden trends.
What to Watch Next for QDEL Investors
One thing I'm watching closely is upcoming respiratory illness seasons, as fluctuations in flu and COVID-19 cases directly affect QuidelOrtho's Labs and Point-of-Care revenues. Track healthcare sector performance, including reimbursement policies and diagnostic innovation trends. Keep an eye on major holders' positioning and fund flows into healthcare ETFs like XLV. Key catalysts include next earnings for segment breakdowns, macroeconomic shifts in inflation and growth, and competitive dynamics in molecular testing. Risks involve prolonged weak seasonality and regulatory changes in transfusion medicine.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QDEL's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for QDEL moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 instances where the indicator moved out of the overbought zone. In 18 of the 19 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 62 cases where QDEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QDEL as a result. In 71 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
QDEL broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QDEL entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
QDEL moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QDEL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +6.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in 175 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.544) is normal, around the industry mean (4.170). P/E Ratio (-0.913) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.274) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. QDEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic healthcare solutions
Industry MedicalNursingServices
Advertisement